India’s Glenmark begins Covid-19 trials with antiviral tablet Favipiravir

This article was originally published here

The company has secured approval from the Drugs Controller General of India (DCGI) to begin the trial with Favipiravir at the end of April. Favipiravir is a generic

The post India’s Glenmark begins Covid-19 trials with antiviral tablet Favipiravir appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply